Author’s note: On Thursday, April 11, the plaintiff who filed the shareholder lawsuit against Taysha Gene Therapies withdrew the suit “without prejudice,” according to an updated filing with Delaware’s Chancery court. No other details were provided.
I regret being caught unaware of the suit’s dismissal prior to publishing the article below. The fairness of PIPEs, particularly the preferential sharing of confidential, stock-moving information, remains an unsettled question, but for now, it’s not one that’s being adjudicated in a court case at this time.
The fairness of PIPEs, particularly the preferential sharing of confidential, stock-moving information, is now a legal question.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect